Suppression of induced pluripotent stem cell generation by the p53–p21 pathway (original) (raw)

Nature volume 460, pages 1132–1135 (2009)Cite this article

Abstract

Induced pluripotent stem (iPS) cells can be generated from somatic cells by the introduction of Oct3/4 (also known as Pou5f1), Sox2, Klf4 and c-Myc, in mouse1,2,3,4 and in human5,6,7,8. The efficiency of this process, however, is low9. Pluripotency can be induced without c-Myc, but with even lower efficiency10,11. A p53 (also known as TP53 in humans and Trp53 in mice) short-interfering RNA (siRNA) was recently shown to promote human iPS cell generation12, but the specificity and mechanisms remain to be determined. Here we report that up to 10% of transduced mouse embryonic fibroblasts lacking p53 became iPS cells, even without the Myc retrovirus. The p53 deletion also promoted the induction of integration-free mouse iPS cells with plasmid transfection. Furthermore, in the _p53_-null background, iPS cells were generated from terminally differentiated T lymphocytes. The suppression of p53 also increased the efficiency of human iPS cell generation. DNA microarray analyses identified 34 p53-regulated genes that are common in mouse and human fibroblasts. Functional analyses of these genes demonstrate that the p53–p21 pathway serves as a barrier not only in tumorigenicity, but also in iPS cell generation.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

Microarray data are available at the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) public database under accession number GSE13365.

References

  1. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006)
    Article CAS Google Scholar
  2. Maherali, N. et al. Directly reprogrammed fibroblasts show global epigenetic remodelling and widespread tissue contribution. Cell Stem Cell 1, 55–70 (2007)
    Article CAS Google Scholar
  3. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germ-line competent induced pluripotent stem cells. Nature 448, 313–317 (2007)
    Article ADS CAS Google Scholar
  4. Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES cell-like state. Nature 448, 318–324 (2007)
    Article ADS CAS Google Scholar
  5. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007)
    Article CAS Google Scholar
  6. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007)
    Article ADS CAS Google Scholar
  7. Lowry, W. E. et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl Acad. Sci. USA 105, 2883–2888 (2008)
    Article ADS CAS Google Scholar
  8. Park, I. H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141–146 (2008)
    Article ADS CAS Google Scholar
  9. Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39–49 (2007)
    Article CAS Google Scholar
  10. Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnol. 26, 101–106 (2008)
    Article CAS Google Scholar
  11. Wernig, M., Meissner, A., Cassady, J. P. & Jaenisch, R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10–12 (2008)
    Article CAS Google Scholar
  12. Zhao, Y. et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3, 475–479 (2008)
    Article CAS Google Scholar
  13. de Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl Acad. Sci. USA 99, 2948–2953 (2002)
    Article ADS CAS Google Scholar
  14. Shinmura, K., Bennett, R. A., Tarapore, P. & Fukasawa, K. Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication. Oncogene 26, 2939–2944 (2007)
    Article CAS Google Scholar
  15. Cecchinelli, B. et al. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ. 13, 1994–1997 (2006)
    Article CAS Google Scholar
  16. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063–1066 (2000)
    Article CAS Google Scholar
  17. Bowman, T. et al. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev. 10, 826–835 (1996)
    Article CAS Google Scholar
  18. Stewart, S. A. et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493–501 (2003)
    Article CAS Google Scholar
  19. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T. & Yamanaka, S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322, 949–953 (2008)
    Article ADS CAS Google Scholar
  20. Yamanaka, S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 460, 49–52 (2009)
    Article ADS CAS Google Scholar
  21. Yamanaka, S. A fresh look at iPS cells. Cell 137, 13–17 (2009)
    Article CAS Google Scholar
  22. Aoi, T. et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321, 699–702 (2008)
    Article ADS CAS Google Scholar
  23. Tada, M., Takahama, Y., Abe, K., Nakatsuji, N. & Tada, T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr. Biol. 11, 1553–1558 (2001)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank D. Srivastava for critical reading of the manuscript; M. Narita, A. Okada, N. Takizawa, H. Miyachi and S. Kitano for technical assistance; and R. Kato, S. Takeshima, Y. Ohtsu and E. Nishikawa for administrative assistance. We also thank Y. Sasai and T. Tada for technical advices, T. Kitamura for Plat-E cells and pMXs retroviral vectors, R. Farese for RF8 ES cells, and B. Weinberg and W. Hahn for shRNA constructs. This study was supported in part by a grant from the Leading Project of MEXT, Grants-in-Aid for Scientific Research of JSPS and MEXT, and a grant from the Program for Promotion of Fundamental Studies in Health Sciences of NIBIO (to S.Y.). H. H. is a research student under the Japanese Government (MEXT).

Author Contributions H.H. conducted most of the experiments in this study. K.T. generated iPS cells from T cells and also performed the shRNA experiments. T.I. performed manipulation of mouse embryos, teratoma experiments, and mouse line maintenance. T.A. and O.K. optimized retroviral transduction into T cells. M.N. generated iPS cells with plasmids. K.O. generated the Nanog–GFP reporter mice and the plasmids for iPS cell generation. K.O. and K.T. supervised H.H. S.Y. designed and supervised the study, and prepared the manuscript.

Author information

Authors and Affiliations

  1. Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8507, Japan
    Hyenjong Hong, Kazutoshi Takahashi, Tomoko Ichisaka, Takashi Aoi, Masato Nakagawa, Keisuke Okita & Shinya Yamanaka
  2. Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
    Hyenjong Hong, Masato Nakagawa & Shinya Yamanaka
  3. Yamanaka iPS Cell Special Project, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan
    Tomoko Ichisaka & Shinya Yamanaka
  4. Laboratory for Autoimmune Regulation, RIKEN Center for Allergy and Immunology, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan ,
    Osami Kanagawa
  5. Gladstone Institute of Cardiovascular Disease, San Francisco, California 94158, USA ,
    Shinya Yamanaka

Authors

  1. Hyenjong Hong
    You can also search for this author inPubMed Google Scholar
  2. Kazutoshi Takahashi
    You can also search for this author inPubMed Google Scholar
  3. Tomoko Ichisaka
    You can also search for this author inPubMed Google Scholar
  4. Takashi Aoi
    You can also search for this author inPubMed Google Scholar
  5. Osami Kanagawa
    You can also search for this author inPubMed Google Scholar
  6. Masato Nakagawa
    You can also search for this author inPubMed Google Scholar
  7. Keisuke Okita
    You can also search for this author inPubMed Google Scholar
  8. Shinya Yamanaka
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toShinya Yamanaka.

Supplementary information

PowerPoint slides

Rights and permissions

About this article

Cite this article

Hong, H., Takahashi, K., Ichisaka, T. et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway.Nature 460, 1132–1135 (2009). https://doi.org/10.1038/nature08235

Download citation

Editorial Summary

On iPS cells and p53: role of p53–p21 pathway

Induced pluripotent stem (iPS) cells are generated from mouse and human somatic cells by introduction of four genes. Efficiency of this process, however, is low. Here it is reported that up to 10% of transduced mouse embryonic fibroblasts (MEF) lacking p53 became iPS cells, even without the Myc retrovirus. In the _p53_-null background, iPS cells can be generated from terminally differentiated T lymphocytes. The authors propose that the p53–p21 pathway serves as a barrier not only in tumorigenicity, but also in iPS cell generation.

Associated content